Topics

FDA Grants Psilocybin Second Breakthrough Therapy Designation

07:40 EST 25 Nov 2019 | Medscape

Following last year's granting of breakthrough designation for psilocybin for treatment-resistant depression, the FDA has now extended it to a broader group of patients with major depressive disorder.
Medscape Medical News

Original Article: FDA Grants Psilocybin Second Breakthrough Therapy Designation

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Psilocybin Second Breakthrough Therapy Designation"

Quick Search

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...